Light Sciences Oncology
- Country
- 🇺🇸United States
- Ownership
- -
- Established
- 1994-01-01
- Employees
- -
- Market Cap
- -
- Website
- http://www.lsoncology.com/
A Placebo Controlled Study of MR901 (Talaporfin Sodium Sodium + a Drug-activating Device) for the Relief of Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia
- Conditions
- Benign Prostatic Hyperplasia
- Interventions
- First Posted Date
- 2014-12-29
- Last Posted Date
- 2018-08-08
- Lead Sponsor
- Light Sciences Oncology
- Target Recruit Count
- 225
- Registration Number
- NCT02326454
Study of Light-Activated Talaporfin Sodium in Patients With Lower Urinary Tract Symptoms (LUTS) Due to Benign Prostatic Hyperplasia (BPH)
- Conditions
- Benign Prostatic HyperplasiaLower Urinary Tract Symptoms
- Interventions
- Device: Transurethral illumination with light emitting diodesProcedure: Placement
- First Posted Date
- 2009-06-11
- Last Posted Date
- 2012-11-16
- Lead Sponsor
- Light Sciences Oncology
- Target Recruit Count
- 21
- Registration Number
- NCT00918034
- Locations
- 🇦🇺
Princess Alexandra Hospital, Wolloongabba, Australia
🇳🇿Canterbury Urology Research Trust Hiatt Chambers St. George's Medical Centre, Christchurch, New Zealand
🇦🇺Royal Brisbane and Women's Hospital Center of Clinical Research, Herston, Australia
Phase 1 Study of the Litxâ„¢ BPH System in Patients With Lower Urinary Tract Symptoms (LUTS) Due to Benign Prostatic Hyperplasia (BPH)
- Conditions
- Benign Prostatic HyperplasiaLower Urinary Tract Symptoms
- Interventions
- Procedure: Placement of device in prostate urethraDevice: Transurethral illumination with light emitting diodes (Litxâ„¢ BPH Device)
- First Posted Date
- 2008-07-03
- Last Posted Date
- 2012-11-16
- Lead Sponsor
- Light Sciences Oncology
- Target Recruit Count
- 12
- Registration Number
- NCT00709488
- Locations
- 🇺🇸
Urology San Antonio Research, San Antonio, Texas, United States
🇺🇸Seattle Urological Associates, Seattle, Washington, United States
🇺🇸Integrity Medical Research, Mountlake Terrace, Washington, United States
Phase 3 Trial of Litxâ„¢ Plus Chemotherapy vs. Chemotherapy Only Treating Colorectal Cancer Patients With Recurrent Liver Metastases
- Conditions
- Liver MetastasesNeoplasm MetastasisColorectal NeoplasmsNeoplasm Recurrence, Local
- Interventions
- Drug: FOLFOX4 regimenProcedure: Percutaneous placement of device in liver metastasesDevice: Interstitial light emitting diodesDrug: FOLFIRI regimen
- First Posted Date
- 2007-02-27
- Last Posted Date
- 2015-08-25
- Lead Sponsor
- Light Sciences Oncology
- Target Recruit Count
- 483
- Registration Number
- NCT00440310
- Locations
- 🇧🇦
Clinical Centre of the University of Sarajevo, Institute of Oncology, Sarajevo, Bosnia and Herzegovina
ðŸ‡ðŸ‡·Clinical Centre Zagreb, Clinical Oncology, Zagreb, Croatia
🇩🇪Katholisches Krankenhaus St. Johann Nepomuk, Erfurt, Germany
Phase IIa Safety and Light Dose-escalation Study in Patients With Primary or Recurrent/High-grade Glioma Using the Litxâ„¢ System to Confirm the Zone of Tumor Destruction During the Intraoperative Treatment of Glioma
- Conditions
- GliomaGlioblastoma MultiformeAnaplastic Astrocytoma
- First Posted Date
- 2006-12-08
- Last Posted Date
- 2012-11-16
- Lead Sponsor
- Light Sciences Oncology
- Target Recruit Count
- 18
- Registration Number
- NCT00409214
- Locations
- 🇷🇸
Institute of Neurosurgery, Clinical Centre Serbia, Belgrade, Serbia
A Phase 3 Study of Talaporfin Sodium and Interstitial Light Emitting Diodes Treating Hepatocellular Carcinoma (HCC)
- Conditions
- Liver NeoplasmsCarcinoma, Hepatocellular
- Interventions
- Procedure: Standard CareDevice: Interstitial Light Emitting DiodesProcedure: Percutaneous placement of device in the liver
- First Posted Date
- 2006-07-21
- Last Posted Date
- 2015-01-30
- Lead Sponsor
- Light Sciences Oncology
- Target Recruit Count
- 208
- Registration Number
- NCT00355355
- Locations
- 🇮🇳
Cancer Clinic, Nagpur, India
🇲🇾Island Hospital, Penang, Malaysia
🇵🇱Centralny Szpital Kliniczny MSWiA, Warsaw, Poland
Tumor Ablation With Talaporfin Sodium and Interstitial Light Emitting Diodes Treating Hepatocellular Carcinoma (HCC)
- Conditions
- Carcinoma, HepatocellularLiver Neoplasms
- First Posted Date
- 2005-07-22
- Last Posted Date
- 2007-12-07
- Lead Sponsor
- Light Sciences Oncology
- Target Recruit Count
- 25
- Registration Number
- NCT00122876
- Locations
- 🇨🇳
Kaohsiung Chang Gung Memorial Hospital, Kaohsiung Hsien, Taiwan
🇸🇬National Cancer Centre Singapore, Singapore, Singapore
🇸🇬Singapore General Hospital, Singapore, Singapore